View in EDS

Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Saved in:
Bibliographic Details
Title: Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
Authors: Hasanali ZS; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, Pennsylvania., Epner EM; Department of Hematology/Oncology, New Mexico VA Health Care System, Albuquerque, New Mexico., Feith DJ; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, Virginia., Loughran TP Jr; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, Virginia., Sample CE; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, Pennsylvania. csample@hmc.psu.edu.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 2784-92. Date of Electronic Publication: 2014 Oct 15.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25319394
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hasanali+ZS%22">Hasanali ZS</searchLink>; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Epner+EM%22">Epner EM</searchLink>; Department of Hematology/Oncology, New Mexico VA Health Care System, Albuquerque, New Mexico.<br /><searchLink fieldCode="AU" term="%22Feith+DJ%22">Feith DJ</searchLink>; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, Virginia.<br /><searchLink fieldCode="AU" term="%22Loughran+TP+Jr%22">Loughran TP Jr</searchLink>; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, Virginia.<br /><searchLink fieldCode="AU" term="%22Sample+CE%22">Sample CE</searchLink>; Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, Pennsylvania. csample@hmc.psu.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 2784-92. <i>Date of Electronic Publication: </i>2014 Oct 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25319394
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-14-0593
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2784
    Titles:
      – TitleFull: Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hasanali ZS
      – PersonEntity:
          Name:
            NameFull: Epner EM
      – PersonEntity:
          Name:
            NameFull: Feith DJ
      – PersonEntity:
          Name:
            NameFull: Loughran TP Jr
      – PersonEntity:
          Name:
            NameFull: Sample CE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2014 Dec
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1